Top

International Journal of Clinical Pharmacy

Published in:

26-12-2023 | Imatinib | Review Article

The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review

Authors: Mansour Tobaiqy, Nawal Helmi, Katie MacLure, Sylvia Saade

Published in: International Journal of Clinical Pharmacy | Issue 2/2024

Abstract

Background

Imatinib, a potent inhibitor of targeted protein tyrosine kinases, treats chronic myeloid leukaemia (CML). Data on imatinib-associated changes in hepatic and thyroid functions are limited and conflicting.

Aim

To report the prevalence of hepatic and thyroid toxicity associated with the use of imatinib in CML patients.

Method

Articles for the systematic review were selected from electronic databases (PubMed, CINALH, Web of Science). Readily accessible peer-reviewed full articles in English published 1st January 2000 to 18th July 2023 were included. The search terms included combinations of: imatinib, CML, liver toxicity, hepatic toxicity, thyroid toxicity. Screening of titles, abstracts, full text articles was conducted independently by two reviewers. Inclusions and exclusions were recorded following PRISMA guidelines. Detailed reasons for exclusion were recorded. Included articles were critically appraised.

Results

Ten thousand one hundred and twenty-three CML patients were reported in the 82 included studies corresponding to 21 case reports, 2 case series, 39 clinical trials and 20 observational studies were selected. Excluding case studies/reports, 1268 (12.6%; n = 1268/10046) hepatotoxicity adverse events were reported, of which 64.7% were rated as mild grade I & II adverse events, 363 (28.6%) as severe, grade III and IV adverse events; some led to treatment discontinuation, liver transplantation and fatal consequences. Twenty (35.1%) studies reported discontinuation of imatinib treatment due to the severity of hepatic toxicity. Fourteen (8.4%, n = 14/167) thyroid dysfunction adverse events were reported.

Conclusion

High frequency of mild and severe hepatotoxicity, associated with imatinib in CML patients, was reported in the published literature. Low numbers of mild and manageable thyroid toxicity events were reported.

Available only for authorised users

Iqbal N, Iqbal N. Imatinib: A breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014:357027.

Sacha T. Imatinib in chronic myeloid leukemia: an overview. Mediterr J Hematol Infect Dis. 2014;6(1): e2014007. https://doi.org/10.4084/MJHID.2014.007.CrossRefPubMedPubMedCentral

Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood. 2007;110(8):2828–37. https://doi.org/10.1182/blood-2007-04-038943.CrossRefPubMed

Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879–94. https://doi.org/10.2165/00003088-200544090-00001.CrossRefPubMed

Kennedy JA, Hobbs G. Tyrosine kinase inhibitors in the treatment of chronic-phase CML: strategies for frontline decision-making. Curr Hematol Malig Rep. 2018;13(3):202–11. https://doi.org/10.1007/s11899-018-0449-7.CrossRefPubMedPubMedCentral

Récoché I, Rousseau V, Bourrel R, et al. Drug-drug interactions with imatinib: an observational study. Medicine. 2016;95(40): e5076. https://doi.org/10.1097/MD.0000000000005076.CrossRefPubMedPubMedCentral

Johnson JR, Bross P, Cohen M, et al. Approval summary: Imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res. 2003;9(6):1972–9.PubMed

Mughal TI, Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biol. 2010;4:315–23. https://doi.org/10.2147/BTT.S5775.CrossRef

Atallah E, Durand J, Kantarjian H, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110(4):1233–7. https://doi.org/10.1182/blood-2007-01-070144.CrossRefPubMed

10.

Dhalluin-Venier V, Besson C, Dimet S, et al. Imatinib mesylate-induced acute hepatitis with autoimmune features. Eur J Gastroenterol Hepatol. 2006;18(11):1235–7. https://doi.org/10.1097/01meg.0000243867.56454.13.CrossRefPubMed

11.

Al Sobhi E, Zahrani Z, Zevallos E, et al. Imatinib-induced immune hepatitis: case report and literature review. J Hematol. 2007;12(1):49–53. https://doi.org/10.1080/10245330600937929.CrossRef

12.

Fisher K, Vuppalanchi R, Saxena R. Drug-induced liver injury. Arc Pathol Lab Med. 2015;139(7):876–87. https://doi.org/10.5858/arpa.2014-0214-RA.CrossRef

13.

Gleevec® (imatinib mesylate) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s060lbl.pdf. Accessed 5 Dec 2023

14.

Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Safe. 2013;36(7):491–503. https://doi.org/10.1007/s40264-013-0048-4.CrossRef

15.

Wang Z, Wang X, Wang Z, et al. Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs imatinib among patients with chronic myeloid leukemia: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(7): e2120165. https://doi.org/10.1001/jamanetworkopen.2021.20165.CrossRefPubMedPubMedCentral

16.

Steegmann JL, Baccarani M, Breccia M, et al. European Leukaemia Net recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukaemia. 2016;30(8):1648–71. https://doi.org/10.1038/leu.2016.104.CrossRef

17.

Kim TD, Schwarz M, Nogai H, et al. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in philadelphia chromosome-positive chronic myeloid leukemia. Thyroid. 2010;20(11):129–1214. https://doi.org/10.1089/thy.2010.0251.CrossRef

18.

de Groot J, Zonnenberg BA, Plukker J, et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharm Therap. 2005;78(4):433–8. https://doi.org/10.1016/j.clpt.2005.06.010.CrossRefPubMed

19.

MacLure K, Tobaiqy M, Stewart D. Imatinib associated with hepatic and thyroid toxicity: A systematic review. 2019. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42019121359 Accessed 5 Sep 2023

20.

MacLure K, Paudyal V, Stewart D. Reviewing the literature, how systematic is systematic? Int J Clin Pharm. 2016;38(3):685–94. https://doi.org/10.1007/s11096-016-0288-3.CrossRefPubMedPubMedCentral

21.

Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P): elaboration and explanation. BMJ. 2015;349: g7647. https://doi.org/10.1136/bmj.g7647.CrossRef

22.

Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. https://doi.org/10.1016/0197-2456(95)00134-4.CrossRefPubMed

23.

Hartling L, Milne A, Hamm MP, et al. Testing the newcastle ottawa scale showed low reliability between individual reviewers. J Clin Epidemiol. 2013;66(9):982–93. https://doi.org/10.1016/j.jclinepi.2013.03.003.CrossRefPubMed

24.

Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. BMJ EBM. 2018;23(2):60–3. https://doi.org/10.1136/bmjebm-2017-110853.CrossRef

25.

Sampayo-Cordero M, Miguel-Huguet B, Malfettone A, et al. The value of case reports in systematic reviews from rare diseases. The example of enzyme replacement therapy (ERT) in patients with mucopolysaccharidosis type II (MPS-II). Int J Environ Res Public Health. 2020;17(18):6590. https://doi.org/10.3390/ijerph17186590.CrossRefPubMedPubMedCentral

26.

Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231–7. https://doi.org/10.1200/JCO.2017.74.7162.CrossRefPubMed

27.

Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. NEJM. 2017;376(10):917–27. https://doi.org/10.1056/NEJMoa1609324.CrossRefPubMed

28.

O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. NEJM. 2003;348(11):994–1004. https://doi.org/10.1056/NEJMoa022457.CrossRefPubMed

29.

Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. NEJM. 2006;355(23):2408–17. https://doi.org/10.1056/NEJMoa062867.CrossRefPubMed

30.

Brümmendorf TH, Cortes JE, Milojkovic D, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: Final results from the BFORE trial. Leukemia. 2022;36(7):1825–33. https://doi.org/10.1038/s41375-022-01589-y.CrossRefPubMedPubMedCentral

31.

Kantarjian H, Shah NP, Shah S, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. NEJM. 2010;362(24):2260–70. https://doi.org/10.1056/NEJMoa1002315.CrossRefPubMed

32.

Saglio G, Kim D, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. NEJM. 2010;362(24):2251–9. https://doi.org/10.1056/NEJMoa0912614.CrossRefPubMed

33.

Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–54. https://doi.org/10.1038/leu.2016.5.CrossRefPubMedPubMedCentral

34.

Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40. https://doi.org/10.1200/JCO.2015.64.8899.CrossRefPubMedPubMedCentral

35.

Petzer AL, Wolf D, Gercheva L, et al. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: First results from the randomized CELSG phase III CML 11 “ISTAHIT” study. Haematologica. 2010;95(6):908–13. https://doi.org/10.3324/haematol.2009.013979.CrossRefPubMedPubMedCentral

36.

Cortes JE, Kim D, Gambacorti-Passerini C, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486–92. https://doi.org/10.1200/JCO.2011.38.7522.CrossRefPubMedPubMedCentral

37.

Preudhomme C, Guilhot F, Guilhot J, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. NEJM. 2010;363(26):2511–21. https://doi.org/10.1056/NEJMoa1004095.CrossRefPubMed

38.

Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood. 2002;99(10):3530–9. https://doi.org/10.1182/blood.V99.10.3530.CrossRefPubMed

39.

Ohnishi K, Nakaseko C, Takeuchi J, et al. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci. 2012;103(6):1071–8. https://doi.org/10.1111/j.1349-7006.2012.02253.x.CrossRefPubMedPubMedCentral

40.

Miranda MB, Lauseker M, Kraus M, et al. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML study IV. Leukemia. 2016;30(6):1255–62. https://doi.org/10.1038/leu.2016.20.CrossRefPubMedPubMedCentral

41.

Cortes J, Quintás-Cardama A, Jones D, et al. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia. Cancer. 2011;117(3):572–80. https://doi.org/10.1002/cncr.25438.CrossRefPubMed

42.

Tong W, Kantarjian H, O’Brien S, et al. Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer. 2011;116(13):3152–9. https://doi.org/10.1002/cncr.25071.CrossRef

43.

Rosti G, Martinelli G, Bassi S, et al. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood. 2004;103(6):2284–90. https://doi.org/10.1182/blood-2003-07-2575.CrossRefPubMed

44.

Kantarjian HM, Cortes JE, O’Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with philadelphia chromosome–positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003;101(1):97–100. https://doi.org/10.1182/blood-2002-02-0545.CrossRefPubMed

45.

Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) Blood. Am J Hematol. 2012;119(5):1123–9. https://doi.org/10.1182/blood-2011-08-376087.CrossRef

46.

Cortes J, Giles F, O’Brien S, et al. Result of high-dose imatinib mesylate in patients with philadelphia chromosome positive chronic myeloid leukemia after failure of interferon-α. Blood. 2003;102(1):83–6. https://doi.org/10.1182/blood-2003-01-0025.CrossRefPubMed

47.

Cerrano M, Crisà E, Pregno P, et al. Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients. Am J Hematol. 2013;88(10):838–42. https://doi.org/10.1002/ajh.23501.CrossRefPubMed

48.

Gambacorti-Passerini C, Cortes JE, Lipton JH, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014;89(10):947–53. https://doi.org/10.1002/ajh.23788.CrossRefPubMedPubMedCentral

49.

Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99(6):1928–37. https://doi.org/10.1182/blood.V99.6.1928.CrossRefPubMed

50.

Champagne MA, Fu CH, Chang M, et al. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the children’s oncology group. Pediat Blood Cancer. 2011;57(1):56–62. https://doi.org/10.1002/pbc.23031.CrossRef

51.

Castagnetti F, Palandri F, Amabile M, et al. Results of high-dose imatinib mesylate in intermediate sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML working party. Blood. 2009;113(15):3428–34. https://doi.org/10.1182/blood-2007-08-103499.CrossRefPubMed

52.

Wang J, Shen Z, Saglio G, et al. Phase 3 study of nilotinib vs imatinib in chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood. 2015;125:2771–8. https://doi.org/10.1182/blood-2014-09-601674.CrossRefPubMedPubMedCentral

53.

Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-treatment. Blood. 2008;111(3):1039–43. https://doi.org/10.1182/blood-2007-07-103523.CrossRefPubMed

54.

Hjorth-Hansen H, Stenke L, Söderlund S, et al. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol. 2015;94(3):243–50. https://doi.org/10.1111/ejh.12423.CrossRefPubMed

55.

Gotta V, Widmer N, Decosterd LA, et al. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. Cancer Chemother Pharmacol. 2014;74(6):1307–19. https://doi.org/10.1007/s00280-014-2599-1.CrossRefPubMed

56.

Millot F, Guilhot J, Nelken B, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia. 2006;20(2):187–92. https://doi.org/10.1038/sj.leu.2404051.CrossRefPubMed

57.

Breccia M, Stefanizzi C, Cannella L, et al. Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia. Leuk Lymphoma. 2008;49(12):2328–32. https://doi.org/10.1080/10428190802578841.CrossRefPubMed

58.

Kolb EA, Pan Q, Ladanyi M, et al. Imatinib mesylate in philadelphia chromosome-positive leukemia of childhood. Cancer. 2003;98(12):2643–50. https://doi.org/10.1002/cncr.11895.CrossRefPubMed

59.

Harbaum L, Marx A, Goekkurt E, et al. Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity. Int J Hematol. 2014;99(1):91–4. https://doi.org/10.1007/s12185-013-1474-x.CrossRefPubMed

60.

Marquinez-Alonso I, Escudero-Vilaplana V, Osorio S, et al. Evaluation of the use, effectiveness and safety of tyrosine kinase inhibitors in chronic myelogenous leukaemia in a general university hospital. Eur J Hosp Pharm. 2020;27:299–301. https://doi.org/10.1136/ejhpharm-2017-001378.CrossRefPubMedPubMedCentral

61.

Aziz Z, Iqbal J, Akram M, et al. Treatment of chronic myeloid leukemia in the imatinib era. Cancer. 2007;109(6):1138–45. https://doi.org/10.1002/cncr.22498.CrossRefPubMed

62.

Mukhopadhyay A, Dasgupta S, Mukhopadhyay S, et al. Imatinib mesylate therapy in patients of chronic myeloid leukemia with philadelphia chromosome positive: an experience from eastern india. Indian J Hematol Blood Transfus. 2012;28(2):82–8. https://doi.org/10.1007/s12288-011-0108-9.CrossRefPubMed

63.

Linga VG, Ganta RR, Kalpathi KI, et al. Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase: In pursuit of perfection. South Asian J Cancer. 2014;3(4):203–5. https://doi.org/10.4103/2278-330X.142961.CrossRefPubMedPubMedCentral

64.

Shin H, Choi SY, Kee K, et al. Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia. Int J Hematol. 2020;111(3):417–26. https://doi.org/10.1007/s12185-019-02805-9.CrossRefPubMed

65.

Alsobhi E, Abrar MB, Abdelaal M, et al. Response to imatinib therapy in adult patients with chronic myeloid leukemia in saudi population: A single-center study. Leuk Lymphoma. 2015;56(4):882–6. https://doi.org/10.3109/10428194.2014.935365.CrossRefPubMed

66.

Rodia R, Pani F, Caocci G, et al. Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors. J Endocrinol Invest. 2022;45(2):291–300. https://doi.org/10.1007/s40618-021-01613-5.CrossRefPubMed

67.

Zaucha JM, Prejzner W, Hellmann A, et al. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;36(5):417–24. https://doi.org/10.1038/sj.bmt.1705087.CrossRefPubMed

68.

Cortes JE, Baccarani M, Moiraghi B, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010;28(3):424–30. https://doi.org/10.1200/JCO.2009.25.3724.CrossRefPubMed

69.

Simonsson B, Gedde-Dahl T, Markevärn B, et al. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood. 2011;118(12):3228–35. https://doi.org/10.1182/blood-2011-02-336685.CrossRefPubMed

70.

Ridruejo E, Cacchione R, Villamil AG, et al. Imatinib-induced fatal acute liver failure. World J Gastroenterol WJG. 2007;13(48):6608–11. https://doi.org/10.3748/wjg.v13.i48.6608.CrossRefPubMed

71.

Han JM, Yee J, Cho YS, et al. Factors influencing imatinib-induced hepatotoxicity. Cancer Res Treat. 2020;52(1):181–8. https://doi.org/10.4143/crt.2019.131.CrossRefPubMed

72.

Kong JH, Yoo S, Lee KE, et al. Early imatinib mesylate-induced hepatotoxicity in chronic myelogenous leukaemia. Acta Haematol. 2007;118(4):205–8. https://doi.org/10.1159/000111092.CrossRefPubMed

73.

Gupta S, Bhatt VR, Varma S. Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone. BMJ Case Rep. 2011;2011(feb21 2):bcr1120103516. https://doi.org/10.1136/bcr.11.2010.3516.CrossRefPubMedPubMedCentral

74.

Lopina N, Dyagil I, Hamov D, et al. Case report of acute toxic imatinib-induced hepatitis in a patient with chronic myeloid leukemia, sulfa allergy, and rheumatoid arthritis. Cureus. 2018;10(8): e3136. https://doi.org/10.7759/cureus.3136.CrossRefPubMedPubMedCentral

75.

Ayoub WS, Geller SA, Tran T, et al. Imatinib (Gleevec)-induced. Hepatotoxicity. 2005;39(1):75–7. https://doi.org/10.1097/01.mcg.0000148444.58167.a6.CrossRef

76.

Bee PC, Gan GG, The A, et al. Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience. Med J Malays. 2006;61(5):547–52.

77.

Bhatty O, Selim M, Kassim T, et al. A case of imatinib-induced hepatitis. Cureus. 2017;9(6): e1302. https://doi.org/10.7759/cureus.1302.CrossRefPubMedPubMedCentral

78.

Cross TJS, Bagot C, Portmann B, et al. Imatinib mesylate as a cause of acute liver failure. Am J Hematol. 2006;81(3):189–92. https://doi.org/10.1002/ajh.20486.CrossRefPubMed

79.

Ferrero D, Pogliani EM, Rege-Cambrin G, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica. 2006;91(6):e78–80.

80.

Harding DJ, MacQuillan G, Howman R, et al. Successful use of dasatinib after liver transplantation for imatinib-induced fulminant liver failure in chronic myeloid leukemia. J Clin Oncol. 2016;34(11):e97–8. https://doi.org/10.1200/JCO.2013.50.1320.CrossRefPubMed

81.

Ikuta K, Torimoto Y, Jimbo J, et al. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management. Int J Hematol. 2005;82(4):343–6. https://doi.org/10.1532/IJH97.05034.CrossRefPubMed

82.

Kikuchi S, Muroi K, Takahashi S, et al. Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes. Leuk Lymphoma. 2004;45(11):2349–51. https://doi.org/10.1080/10428190412331272721.CrossRefPubMed

83.

Lai G, Yan S, Chang C, et al. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol:WJG. 2013;19(8):1318–21. https://doi.org/10.3748/wjg.v19.i8.1318.CrossRefPubMed

84.

Maiti B, Setrakian S, Daw HA. Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report. Cases J. 2009;2(1):7526. https://doi.org/10.1186/1757-1626-2-7526.CrossRefPubMedPubMedCentral

85.

Nacif LS, Waisberg DR, Pinheiro RS, et al. Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report. J Med Case Rep. 2018;12(1):63. https://doi.org/10.1186/s13256-018-1588-0.CrossRefPubMedPubMedCentral

86.

Singh S, Sharma P. Imatinib-induced thyroiditis in philadelphia chromosome-positive chronic myeloid leukemia. Indian J Pharmacol. 2016;48(4):458–9. https://doi.org/10.4103/0253-7613.186214.CrossRefPubMedPubMedCentral

87.

Thia TJK, Tan HH, Chuah THC, et al. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. Singap Med J. 2008;49(3):e86–9.

88.

Yamazaki R, Okamoto S, Chen C, et al. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase. Leuk Lymphoma. 2006;47(7):1427–30. https://doi.org/10.1080/10428190600593877.CrossRefPubMed

89.

Zhang B, Chen Y, Lv J, et al. Comparison of the efficacy of nilotinib and imatinib in the treatment of chronic myeloid leukemia. J Coll Phys Surg Pak. 2019;29(7):631–4. https://doi.org/10.29271/jcpsp.2019.07.631.CrossRef

90.

Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440–53. https://doi.org/10.1038/s41375-020-01111-.CrossRefPubMedPubMedCentral

91.

Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. NEJM. 2001;344(14):1031–7. https://doi.org/10.1056/NEJM200104053441401.CrossRefPubMed

92.

Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. NEJM. 2002;346(9):645–52. https://doi.org/10.1056/NEJMoa011573.CrossRefPubMed

93.

Kantarjian HM, Cortes J, O’Brien S, et al. Imatinib mesylate (STI571) therapy for philadelphia chromosome–positive chronic myelogenous leukemia in blast phase. Blood. 2002;99(10):3547–53. https://doi.org/10.1182/blood.V99.10.3547.CrossRefPubMed

94.

Kantarjian HM, O’Brien S, Cortes JE, et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002;8(7):2167–76.PubMed

95.

Kantarjian HM, O’Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002;100(5):1590–5. https://doi.org/10.1182/blood.V100.5.1590.h81702001590_1590_1595.CrossRefPubMed

96.

Cervantes F, Hernandez-Boluda JC, Steegmann JL, et al. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: Results and prognostic factors for response and progression-free survival in 150 patients. Haematologica. 2003;88(10):1117–22. https://www.haematologica.org/article/view/2872

97.

Cervantes F, Herna’ndez-Boluda J, Odriozola J, et al. Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. Br J Haematol. 2003;120(3):500–4. https://doi.org/10.1046/j.1365-2141.2003.04077.x.CrossRefPubMed

98.

Brümmendorf TH, Cortes JE, Souza CA, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2014;168(1):69–81. https://doi.org/10.1111/bjh.13108.CrossRefPubMedPubMedCentral

99.

Arora B, Kumar L, Kumari M, et al. Therapy with imatinib mesylate for chronic myeloid leukaemia. Indian J Med Paediatr Oncol. 2005;26(2):5–17. https://doi.org/10.1055/s-0041-1733114.CrossRef

100.

Deininger M, Schleuning M, Greinix H, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica. 2006;91(4):452–9.PubMed

101.

Kayastha GK, Gurung P, Acharya PK, et al. Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor. BMC Hematol. 2010;10:1–7.

102.

Kang MK, Lee HJ, Choi JH. Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor. Yeungnam Univ J Med. 2019;36(2):155–8. https://doi.org/10.12701/yujm.2019.00115.CrossRefPubMedPubMedCentral

103.

Mindikoglu AL, Regev A, Bejarano PA, et al. Imatinib mesylate (Gleevec) hepatotoxicity. Dig Dis Sci. 2007;52:598–601.

104.

Phillips R, Hazell L, Sauzet O, et al. Analysis and reporting of adverse events in randomised controlled trials: a review. BMJ Open. 2019;9(2): e024537. https://doi.org/10.1136/bmjopen-2018-024537.CrossRefPubMedPubMedCentral

105.

Haq MI, Nixon J, Stanley AJ. Imatinib and liver toxicity. BMJ Case Rep. 2018;11(1): e226740. https://doi.org/10.1136/bcr-2018-226740.CrossRefPubMedPubMedCentral

106.

Seidel C, Fenner M, Länger F, et al. Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST). BMC Cancer. 2012;12(1):186. https://doi.org/10.1186/1471-2407-12-186.CrossRefPubMedPubMedCentral

107.

Pariente A, Etcharry F, Cales V, et al. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. Eur J Gastro Hepatol. 2006;18(7):785–7. https://doi.org/10.1097/01.meg.0000216941.42306.0e.CrossRef

108.

Tonyali O, Coskun U, Yildiz R, et al. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Med Oncol. 2010;27(3):768–73. https://doi.org/10.1007/s12032-009-9284-y.CrossRefPubMed

109.

Yachoui R. Early onset imatinib Mesylate-Induced hepatotoxicity in a patient with gastrointestinal stromal tumors. Am J Ther. 2014;21(5):e148–50. https://doi.org/10.1097/MJT.0b013e31826fc5d1.CrossRefPubMed

110.

Bilgi N, Bell K, Ananthakrishnan AN, et al. Imatinib and panax ginseng: a potential interaction resulting in liver toxicity. Ann Pharmacother. 2010;44(5):926–8. https://doi.org/10.1345/aph.1M715.CrossRefPubMed

111.

Huang F, Fang W, Cheng Z, et al. Imatinib-induced hepatotoxicity via oxidative stress and activation of NLRP3 inflammasome: an in vitro and in vivo study. Arch Toxicol. 2022;96(4):1075–87. https://doi.org/10.1007/s00204-022-03245-x.CrossRefPubMed

112.

Ahmadieh H, Salti I. Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment. BioMed Res Int. 2013; 725410-9. doi:https://doi.org/10.1155/2013/725410

113.

Breccia M, Molica M, Alimena G. How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review. Leuk Res. 2014;38(12):1392–8. https://doi.org/10.1016/j.leukres.2014.09.016.CrossRefPubMed

114.

Hershman JM, Liwanpo L. How does sunitinib cause hypothyroidism? Thyroid. 2010;20(3):243–4. https://doi.org/10.1089/thy.2010.1620.CrossRefPubMed

115.

Illouz F, Laboureau-Soares S, Dubois S, et al. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol. 2009;160(3):331–6. https://doi.org/10.1530/EJE-08-0648.CrossRefPubMed

116.

Lechner MG, Vyas CM, Hamnvik OR, et al. Risk factors for new hypothyroidism during tyrosine kinase inhibitor therapy in advanced nonthyroidal cancer patients. Thyroid. 2018;28(4):437–44. https://doi.org/10.1089/thy.2017.0579.CrossRefPubMed

117.

Rogiers A, Wolter P, de Beeck KO, et al. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid. 2010;20(3):317–22. https://doi.org/10.1089/thy.2009.0125.CrossRefPubMed

118.

Desai J, Yassa L, Alexander EK, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006;145(9):660–4. https://doi.org/10.7326/0003-4819-145-9-200611070-00008.CrossRefPubMed

119.

Makita N, Miyakawa M, Fujita T, et al. Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid. 2010;20(3):323–6. https://doi.org/10.1089/thy.2009.0414.CrossRefPubMed

120.

Faris JE, Moore AF, Daniels GH. Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid. 2007;17(11):1147–9. https://doi.org/10.1089/thy.2007.0104.CrossRefPubMed

121.

Grossmann M, Premaratne E, Desai J, et al. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol. 2008;69(4):669–72. https://doi.org/10.1111/j.1365-2265.2008.03253.x.CrossRef

122.

Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007;17(4):351–5. https://doi.org/10.1089/thy.2006.0308.CrossRefPubMed

123.

Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Meta. 2007;92(9):3531–4. https://doi.org/10.1210/jc.2007-0586.CrossRef

124.

Garfield D, Hercbergs A, Davis P. Unanswered questions regarding the management of sunitinib-induced hypothyroidism. Nat Clin Prac Oncol. 2007;4(12):674. https://doi.org/10.1038/ncponc0998.CrossRef

125.

Jonklaas J, Bianco AC, Bauer AJ, Burman KD et al. American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec;24(12):1670–751. https://doi.org/10.1089/thy.2014.0028

Title: The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review
Authors: Mansour Tobaiqy
Nawal Helmi
Katie MacLure
Sylvia Saade
Publication date: 26-12-2023
Publisher: Springer International Publishing
Keywords: Imatinib
Chronic Myeloid Leukemia
Published in: International Journal of Clinical Pharmacy / Issue 2/2024
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI: https://doi.org/10.1007/s11096-023-01671-0

2024 ESC Congress

Noise pollution dangerous for heart health

02-09-2024
Myocardial Infarction
News

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Antihypertensives: more effective at morning or night?

02-09-2024
Hypertension
News

Low Lp(a) levels unlikely to increase the risk of diabetes

02-09-2024
Type 2 Diabetes
News

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

EASD 2024

Springer Medicine

The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review

Abstract

Background

Aim

Method

Results

Conclusion

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials

EASD 2024

Springer Medicine

Abstract

Background

Aim

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2024

Writing a manuscript for publication in a peer-reviewed scientific journal: Guidance from the European Society of Clinical Pharmacy

Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer

Communication skills-based training about medication switch encounters: pharmacy staff and patients’ experiences

Management of iron deficiency in women of childbearing age with oral iron intolerance: a prospective, randomised, controlled trial of three doses of an iron-whey-protein formulation

Financial impact of medication reviews by clinical pharmacists to reduce in-hospital adverse drug events: a return-on-investment analysis

Accuracy in patient-reported adverse drug reactions and their recognition: a mixed-methods study

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials